On June 26-28, 2012, CPhI, ICSE & BioPh China were heldat Shanghai New International Exhibition Center (SNIEC). Jointly organized byUBM International Media and China Chamber of Commerce of Medicines & HealthProducts Importers & Exporters, the exhibition mainly exhibited activepharmaceutical ingredients (API), chemicals and intermediates, auxiliarymaterial and dosage forms, natural extracts, contract R&D outsourcing,contract production outsourcing, reagents, biotechnology and other products.Four API and intermediate manufacturing subsidiaries of Fosun Pharma, namelyGuilin Pharmaceutical Co., Ltd., Chongqing Pharmaceutical Research InstituteCo., Ltd. (CPRI) (together with Chongqing Kangle Pharmaceutical Co., Ltd.),Shine Star (Hubei) Biological Engineering Co., Ltd., and Chongqing YaoPharmaceutical Co., Ltd. (together with Chongqing Carelife Pharmaceutical Co.,Ltd.) attended the exhibition as a group with more than 100 products.

Designed in the image of FosunPharma Groupas a whole, the booths paid attention to reveal product featuresof all membercompanies while giving full exposure to the group’s brand.Compared with lastexhibition, locations of the booths that Fosun Pharma obtainedas a group weremore ideal. With a simple but bright design, clearly dividedfunctional areas,comfortably matched colors, the booths were vast in space,making all customersand participating companies contented with contentsexhibited and the environment.All member companies took advantage of all opportunitiesduring the exhibitionto visit old customers and make new friends, activelyopening up new channels,seeking new opportunities for businesses in the secondhalf of the year andextending to a wider space while strengthening existingbusinesses.

API and intermediate products manufactured byChongqing Carelife, a subsidiary of Chongqing Yao Pharma has already enjoyed highreputation at home and abroad. This year, the exhibition gave ChongqingCarelife an opportunity to contact more global manufacturers. As revealed byWang Fengling from the business department of Chongqing Carelife, APIpharmaceutics, including clindamycin hydrochloride, that have already been bestsellers have become mainstream products in the industry. This year, ChongqingCarelife newly developed entecavir and epinastine hydrochloride. Customers cameto consult one after another. Currently, responses from the market are strong.

This year, CPRI has gained greaterrecognition in Europe and South Asia.Tigecycline, oxiracetam and donepezil newly launched by the company have gainedfavors from enterprises from the United Statesand Israelrespectively. As sugguested by Wang Yachuan, GM of Chongqing Kangle, these newproducts had attracted a lot of new partners with the intent to cooperate afterdisplayed on the exhibition. Due to excessive demands, he was forced to askthat in principle, the time for a conversation should be no more than 1 hour.

Inaddition, EU issued Directive 2011/62/EU in 2011, making new requirements for China’s GMPsystem. Expected to take effect in July 2013, the directive is intended toincrease the threshold for medicine import, and prevent counterfeit andinferior API from being placed on EU market. Shine Star (Hubei) will have itsplant completely relocated this year, by which its production capacity andtechnology shall be improved. As indicated by Dong Xiaolu, deputy GM ofmarketing, major markets of the company are currently in Europe and America, withthe focus on European enterprises. At this year’s exhibition, a great number ofold customers who visited its booth talked about the problem of new Europeanstandard. Therefore, in the remaining 1 year, Shine Star shall have to get usedto the new standard in time and make efforts to keep its current absolutely dominantposition. Shine Star is very confident in this.